---
category: news
title: "BenevolentAI Says Achieves Third Milestone In AI-enabled Drug Discovery Collaboration With AZN"
excerpt: "(AZN.L, AZN) has selected an additional novel target for idiopathic pulmonary fibrosis for its drug development portfolio, resulting in a milestone payment to BenevolentAI, the clinical-stage AI-enabled drug discovery company said in a statement."
publishedDateTime: 2022-05-17T05:16:00Z
originalUrl: "https://www.nasdaq.com/articles/benevolentai-says-achieves-third-milestone-in-ai-enabled-drug-discovery-collaboration-with"
webUrl: "https://www.nasdaq.com/articles/benevolentai-says-achieves-third-milestone-in-ai-enabled-drug-discovery-collaboration-with"
ampWebUrl: "https://www.nasdaq.com/articles/benevolentai-says-achieves-third-milestone-in-ai-enabled-drug-discovery-collaboration-with?amp"
cdnAmpWebUrl: "https://www-nasdaq-com.cdn.ampproject.org/c/s/www.nasdaq.com/articles/benevolentai-says-achieves-third-milestone-in-ai-enabled-drug-discovery-collaboration-with?amp"
type: article
quality: 55
heat: 55
published: false

provider:
  name: Nasdaq
  domain: nasdaq.com

topics:
  - AI

secured: "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;F5BiUJ9A7/GNqnuTOlXefw=="
---

